These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 36138495)
1. Antibody response 6 months after the booster dose of Pfizer in previous recipients of CoronaVac. Silva MFS; Pinto ACMD; de Oliveira FCE; Caetano LF; Araújo FMC; Fonseca MHG J Med Virol; 2023 Jan; 95(1):e28169. PubMed ID: 36138495 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. Yavuz E; Günal Ö; Başbulut E; Şen A J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796 [TBL] [Abstract][Full Text] [Related]
3. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ; Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136 [TBL] [Abstract][Full Text] [Related]
4. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers. Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106 [TBL] [Abstract][Full Text] [Related]
5. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study. Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC; Front Immunol; 2022; 13():918896. PubMed ID: 35757764 [TBL] [Abstract][Full Text] [Related]
7. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
8. Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines. Atıcı S; Soysal A; Gönüllü E; Aydemir G; Öner N; Alan S; Engin H; Yıldız M; Karaböcüoğlu M Rev Soc Bras Med Trop; 2023; 56():e00462023. PubMed ID: 37493731 [TBL] [Abstract][Full Text] [Related]
9. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
10. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279 [TBL] [Abstract][Full Text] [Related]
11. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine. Fonseca MHG; Pinto ACMD; Silva MFS; de Melo ACL; Vasconcelos GS; Dos Santos ER; de Carvalho Araújo FM; de Andrade LOM Emerg Infect Dis; 2022 Jun; 28(6):1237-1240. PubMed ID: 35421324 [TBL] [Abstract][Full Text] [Related]
12. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738 [TBL] [Abstract][Full Text] [Related]
13. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19]. Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968 [TBL] [Abstract][Full Text] [Related]
15. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. Çağlayan D; Süner AF; Şiyve N; Güzel I; Irmak Ç; Işik E; Appak Ö; Çelik M; Öztürk G; Alp Çavuş S; Ergör G; Sayiner A; Ergör A; Demiral Y; Kiliç B J Med Virol; 2022 May; 94(5):2212-2221. PubMed ID: 35075655 [TBL] [Abstract][Full Text] [Related]
16. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults. Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053 [TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors. Venerito V; Stefanizzi P; Martinelli A; Fornaro M; Galeone MG; Tafuri S; Iannone F; Lopalco G Clin Exp Rheumatol; 2023 Jan; 41(1):166-169. PubMed ID: 36441661 [TBL] [Abstract][Full Text] [Related]
19. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676 [TBL] [Abstract][Full Text] [Related]
20. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. Filardi BA; Monteiro VS; Schwartzmann PV; do Prado Martins V; Zucca LER; Baiocchi GC; Malik AA; Silva J; Hahn AM; Chen NFG; Pham K; Pérez-Then E; Miric M; Brache V; Cochon L; Larocca RA; Mendez RDR; Bardini Silveira D; Pinto AR; Croda J; Yildirim I; Omer SB; Ko AI; Vermund SH; Grubaugh ND; Iwasaki A; Lucas C; ; Vogels CBF; Breban M; Koch TR; Chaguza C; Tikhonova I; Castaldi C; Mane S; De Kumar B; Ferguson D; Kerantzas N; Peaper D; Landry ML; Schulz W Sci Transl Med; 2023 Feb; 15(683):eade6023. PubMed ID: 36791210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]